Form 8-K - Current report:
SEC Accession No. 0001193125-23-103616
Filing Date
2023-04-17
Accepted
2023-04-17 16:02:53
Documents
14
Period of Report
2023-04-17
Items
Item 8.01: Other Events
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K d465225d8k.htm   iXBRL 8-K 25308
2 EX-99.1 d465225dex991.htm EX-99.1 15747
6 GRAPHIC g465225g0417231430122.jpg GRAPHIC 2334
  Complete submission text file 0001193125-23-103616.txt   175540

Data Files

Seq Description Document Type Size
3 XBRL TAXONOMY EXTENSION SCHEMA inab-20230417.xsd EX-101.SCH 2836
4 XBRL TAXONOMY EXTENSION LABEL LINKBASE inab-20230417_lab.xml EX-101.LAB 18738
5 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE inab-20230417_pre.xml EX-101.PRE 11698
8 EXTRACTED XBRL INSTANCE DOCUMENT d465225d8k_htm.xml XML 3443
Mailing Address EMPIRE STATE BUILDING 350 5TH AVENUE, SUITE 5330 NEW YORK NY 10118
Business Address EMPIRE STATE BUILDING 350 5TH AVENUE, SUITE 5330 NEW YORK NY 10118 (646) 600-6438
IN8BIO, INC. (Filer) CIK: 0001740279 (see all company filings)

EIN.: 825462585 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-39692 | Film No.: 23823961
SIC: 2836 Biological Products, (No Diagnostic Substances)